Patient with multifocal pancreatic insulinoma: a rare presentation of functional pancreatic neuroendocrine neoplasm

Authors

DOI:

https://doi.org/10.30978/GS-2023-2-62

Keywords:

multiple insulinomas, surgical treatment, intraoperative ultrasonography, seizures

Abstract

Insulinoma is a type of neuroendocrine tumour with an incidence of 1—4 cases per million. Multiple insulinomas constitute less than 10% of all insulinomas. Surgery is the treatment of choice for insulinoma. The operation can be done with an open or laparoscopic approach, with cure rates ranging from 77% to 100%. Pancreatic resection is recommended for tumours larger than 2 cm in size, while enucleation is advised for lesions smaller than 2cm if the tumour is at least 2—3 mm away from the main pancreatic duct to prevent the formation of a fistula. For better intraoperative localization of lesions, bimanual palpation together with intraoperative ultrasonography (IOUS) is advised. Palpation alone has 70% sensitivity, but together with IOUS, it reaches 85—95%

A young female patient in her late 20s with non‑specific complaints and a medical history of epilepsy dating back to the age of 17 underwent a physical examination. Blood test results indicated severe hypoglycemia, and magnetic resonance imaging (MRI) revealed an 11‑mm neoplasia in the body of the pancreas. A 72‑hour fasting test confirmed the diagnosis of insulinoma, and the patient underwent laparoscopic surgery. IOUS was done for the precise localization of the lesion, and another tumour in the pancreatic tail was found. A spleen‑preserving laparoscopic distal pancreatectomy was performed. Histologic reports confirmed multifocal Grade 1 insulinoma. The postoperative course was uneventful. After 4 months of follow‑up, computed tomography (CT) was done, and there were no signs of recurrence of insulinoma, pancreatic pseudocysts, or other signs of postoperative complications. Since the operation, the patient has not had any episodes of hypoglycemia or seizures.

The wide spectrum of symptoms, which are not specific to insulinomas, in particular seizures, can make it difficult to establish a correct diagnosis and can be mistaken for other psychiatric or neurologic disorders. This case clearly shows the advantages of IOUS‑guided surgery in achieving better visualization and outcomes. After enucleation of the smaller lesion without the use of IOUS, other insulinomas would be missed and left in place because they were located deeply in the parenchyma. Simple visualization and palpation would not be enough.

 

References

Babic B, Keutgen X, Nockel P, et al. Insulinoma due to multiple pancreatic microadenoma localized by multimodal imaging. J Clin Endocrinol Metab. 2016;101(10):3559-63. http://doi.org/10.1210/jc.2016-2717.

Borazan E, Aytekin A, Yilmaz L, et al. Multifocal insulinoma in pancreas and effect of intraoperative ultrasonography. Case Rep Surg. 2015;2015:375124. http://doi.org/10.1155/2015/375124.

De Herder WW, Hofland J. Insulinoma. In: Feingold KR, Anawalt B, Blackman MR, et al., eds. Endotext. South Dartmouth (MA): MDText.com, Inc.; April 4, 2023.

Falconi M, Eriksson B, Kaltsas G, et al. ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors. Neuroendocrinology. 2016;103(2):153-71. http://doi.org/10.1159/000443171.

Frey S, Mirallié E, Le Bras M, Regenet N. What are the place and modalities of surgical management for pancreatic neuroendocrine neoplasms? A narrative review. Cancers (Basel). 2021;13(23):5954. Published 2021 Nov 26. http://doi.org/10.3390/cancers13235954.

Gamboa-Jiménez TI, Juárez-Aguilar FG. Insulinoma multicéntrico asociado a neoplasia endócrina múltiple tipo 1: reporte de un caso [Multicentric insulinoma associated with multiple endocrine neoplasia type 1: One case report]. Rev Med Inst Mex Seguro Soc. 2018;56(3):316-9. Published 2018 Oct 25.

Inoue C, Nishihama K, Hayasaki A, et al. Case report: a difficult-to-diagnose case of hyperinsulinemic hypoglycemia surgically treated after developing acute pancreatitis. Front Endocrinol (Lausanne). 2021;12:731071. Published 2021 Oct 27. http://doi.org/10.3389/fendo.2021.731071.

Khan Md AR, Wazir MH, Waqar S, Ullah R, Gul A. A rare case of insulinoma in a thin, lean adult male: a case report. Cureus. 2022;14(3):e23414. http://doi.org/10.7759/cureus.23414.

Kurakawa KI, Okada A, Manaka K, et al. Clinical characteristics and incidences of benign and malignant insulinoma using a National Inpatient Database in Japan. J Clin Endocrinol Metab. 2021;106(12):3477-86. http://doi.org/10.1210/clinem/dgab559.

Lam AK, Ishida H. Pancreatic neuroendocrine neoplasms: Clinicopathological features and pathological staging. Histol Histopathol. 2021;36(4):367-82. http://doi.org/10.14670/HH-18-288.

Mathur A, Gorden P, Libutti SK. Insulinoma. Surg Clin North Am. 2009;89(5):1105-21. http://doi.org/10.1016/j.suc.2009.06.009.

Nashidengo PR, Quayson FW, Abebrese JT, Negumbo L, Enssle C, Kidaaga F. Varied presentations of pancreatic insulinoma: a case report. Pan Afr Med J. 2022;42:69. Published 2022 May 25. http://doi.org/10.11604/pamj.2022.42.69.34839.

Niederle B, Selberherr A, Bartsch DK, et al. Multiple endocrine neoplasia type 1 and the Pancreas: Diagnosis and Treatment of Functioning and Non-Functioning Pancreatic and Duodenal Neuroendocrine Neoplasia within the MEN1 Syndrome — An International Consensus Statement. Neuroendocrinology. 2021;111(7):609-30. http://doi.org/10.1159/000511791.

Oberg K, Eriksson B. Endocrine tumours of the pancreas. Best Pract Res Clin Gastroenterol. 2005;19(5):753-81. http://doi.org/10.1016/j.bpg.2005.06.002.

Okabayashi T, Shima Y, Sumiyoshi T, et al. Diagnosis and management of insulinoma. World J Gastroenterol. 2013;19(6):829-37. http://doi.org/10.3748/wjg.v19.i6.829.

Pavel M, Öberg K, Falconi M, Krenning EP, Sundin A, Perren A, Berruti A; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020 Jul;31(7):844-860. http://doi.org/10.1016/j.annonc.2020.03.304. Epub 2020 Apr 6. PMID: 32272208.

Peltola E, Hannula P, Huhtala H, et al. Long-term morbidity and mortality in patients diagnosed with an insulinoma. Eur J Endocrinol. 2021;185(4):577-86. Published 2021 Sep 1. http://doi.org/10.1530/EJE-21-0230.

Roland CL, Lo CY, Miller BS, Holt S, Nwariaku FE. Surgical approach and perioperative complications determine short-term outcomes in patients with insulinoma: results of a bi-institutional study. Ann Surg Oncol. 2008 Dec;15(12):3532-7. http://doi.org/10.1245/s10434-008-0157-y. Epub 2008 Sep 30. PMID: 18825460.

Service FJ, McMahon MM, O’Brien PC, Ballard DJ. Functioning insulinoma — incidence, recurrence, and long-term survival of patients: a 60-year study. Mayo Clin Proc. 1991;66(7):711-9. http://doi.org/10.1016/s0025-6196(12)62083-7.

Shin JJ, Gorden P, Libutti SK. Insulinoma: pathophysiology, localization and management. Future Oncol. 2010;6(2):229-37. http://doi.org/10.2217/fon.09.165.

Snaith JR, McLeod D, Richardson A, Chipps D. Multifocal insulinoma secondary to insulinomatosis: persistent hypoglycaemia despite total pancreatectomy [published online ahead of print, 2020 Dec 24]. Endocrinol Diabetes Metab Case Rep. 2020;2020:20-0091. http://doi.org/10.1530/EDM-20-0091.

Svensson E, Muth A, Hedenström P, Ragnarsson O. The incidence of insulinoma in Western Sweden between 2002 and 2019. Ann Gastroenterol. 2022;35(4):434-40. http://doi.org/10.20524/aog.2022.0707.

Tartaglia A, Busonero G, Gagliardi L, Boddi V, Pieri F, Nizzoli M. Complete remission of recurrent multiple insulin-producing neuroendocrine tumors of the pancreas with somatostatin analogs: a case report and literature review. Discov Oncol. 2022;13(1):66. http://doi.org/10.1007/s12672-022-00531-z

Downloads

Published

2023-11-17

Issue

Section

Clinical Case